Phosphorex Expands Facilities
HOPKINTON, Mass., January 7, 2021 — Phosphorex, Inc., a leading contract development and manufacturing organization (CDMO) specializing in long-acting formulations, nanomedicine and nucleic acid delivery, announced today the acquisition of new laboratory and office space in Hopkinton, MA. The newly added facility consists of 30,000 square foot of state-of-the-art wet chemistry, biochemistry, analytical and engineering laboratories and triples previous capacity, allowing Phosphorex to meet the increasing demand for its products and services.
“We are very excited to secure this leading-edge laboratory space. This will enable us to expand the services we offer to our clients and to facilitate technology development in collaboration with our partners,” remarked Dr. Bin Wu, Founder, President and CEO. “We look forward to continuing to apply our formulation capabilities and delivery technologies to contribute to the advancement of the biotechnology and pharmaceutical sciences.”
Phosphorex is a leading provider of drug delivery technologies and solutions. By harnessing the potential of microspheres and nanoparticles for drug delivery, Phosphorex offers tailored solutions and enabling technologies to optimize a drug’s release rate, targeting ability, bioavailability and deliverability, with the goal of achieving desired therapeutic effects while reducing adverse clinical outcomes. Phosphorex supports pharmaceutical and biotech companies through all phases of their development, from proof of concept to clinical studies. Phosphorex’s mission is to help our partners solve complex problems and develop successful drugs to help patients.